Studies presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium explored the impact of lower dose rituximab on orbital lymphoma and factors associated with survival in conjunctival lymphoma.
During an oncology session at the American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium, experts presented new research on orbital and conjunctival lymphomas.
Chelsea Reighard, MD, MS, of the Department of Ophthalmology, Division of Eye Plastic, Orbital and Facial Cosmetic Surgery at the Kellogg Eye Center in Ann Arbor, Michigan, outlined findings of a study1 assessing whether treatment with intralesional rituximab with fewer doses at higher concentrations constitutes an effective primary treatment of low-grade orbital lymphoma.
“Orbital lymphomas are the most frequent malignancy of the ocular adnexa and comprise about 50 to 60% of all orbital tumors,” said Reighard, while the majority are B-cell in origin. Although orbital lymphomas are typically treated with external beam radiotherapy (EBRT), this treatment can lead to significant ocular morbidity. Rituximab is typically used as a systemic treatment for orbital lymphoma, she added.
Reighard and colleagues carried out a retrospective chart review of patients with biopsy-proven orbital lymphoma who were treated with intralesional rituximab at a single center. Patients with lymphoma in other parts of the eye or those with orbital adnexa were excluded from the analysis.
“We graded each response as either a complete or partial response; complete meaning the complete tumor resolution on imaging, partial meaning decreased tumor type size but not completely resolved on clinical examination and on imaging,” Reighard explained.
A total of 7 eyes from 6 patients were included in the analysis, which showed:
“The side effects were varied but were transient, so anything from post-injection pain, chills, intermittent diplopia, headache, some systemic symptoms as well,” Reighard said. No long-term sequalae were reported.
Overall, results indicated “intralesional rituximab is a suitable in-office primary treatment for low grade orbital lymphoma,” she said. The study’s small sample size and varied follow-up intervals mark limitations.
An additional presentation2 explored factors associated with survival outcomes among patients with conjunctival lymphomas in the United States. Kevin Wu, MD, a third-year ophthalmology resident at Mount Sinai Hospital in New York City, outlined results of the epidemiological study, which used nationally representative data from the Surveillance, Epidemiology, and End Results (SEER) database recorded between 1998 and 2018.
Including data from 1066 patients, it marks the largest epidemiological study conducted on conjunctival lymphomas, while “the cases including this database is estimated to account for approximately 35% of the entire US population,” Wu explained.
Although mean patient age was 59, this factor varied depending on histological subtypes, and 10-year overall survival was 72.1%. “Among the B-cell lineage lymphoma subtypes extra marginal zone lymphoma conferred the best 10 year overall survival at 76%, while mantle cell lymphoma conferred the worst 10 year overall survival at 29.4%,” Wu said.
Multivariate analyses revealed the following negative predictors of overall survival:
Asian or Pacific Islander race was the only positive predictor of overall survival (HR 0.53; 95% CI, 0.31-0.90; P = .018).
In addition, “patients that did not receive chemotherapy had improved disease specific survival,” Wu said. “However, it should be noted that in previous studies, they show the utility of radiation therapy on decreasing rates of recurrence, which was not examined in this study.”
The retrospective design of the study marks a limitation. Wu also noted that treatment modalities have changed throughout the study period.
References
1. Reighard C, Demirci H. Primary treatment of orbital lymphoma with intralesional injections of rituximab. ASOPRS Fall Scientific Symposium; November 11-12, 2021; New Orleans, Louisiana. Accessed November 12, 2021. https://asoprsfall.virtualbyvario.com/wp-content/uploads/2021/10/ASOPRS_2021_fall_syllabus_FINAL.pdf
2. Wu K, Chelnis J. Epidemiology and survival outcomes for primary conjunctival lymphomas in the United States. ASOPRS Fall Scientific Symposium; November 11-12, 2021; New Orleans, Louisiana. Accessed November 12, 2021. https://asoprsfall.virtualbyvario.com/wp-content/uploads/2021/10/ASOPRS_2021_fall_syllabus_FINAL.pdf
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More